US$ 25.11
ascendis pharma glp-1 receptor agonist agonists for individualized treatment of type 2 diabetes mellitus Schematic illustration of monoagonists, dual
Description
Tirzepatide displayed an unprecedented glucose and body weight lowering potential, presenting also with the ability to increase insulin sensitivity, reduce systolic blood pressure and inflammation and ameliorate dyslipidemia, particularly by reducing triglycerides levels

Ozempic alternatives in the GLP-1 family offer effective weight loss pathways

The GLP-1 drugs market size is predicted to grow from USD 58.05 billion in 2026 to USD 132.79 billion by 2035, driven by a CAGR of 9.63%.

GLP-1 is of relevance to ...

Is allulose a GLP-1 agonist

Stock screener for investors and traders, financial visualizations.
